Details of the Drug

General Information of Drug (ID: DMAOL2S)

• Drug Name: Voriconazole
• Synonyms: VCZ; Vfend; Pfizer brand of voriconazole; UK 109496; Voriconazole in combination with MGCD290; DRG-0301; UK 109,496; UK-109496; VFEND (TN); Vfend (TN); Vfend, Voriconazole; UK-109,496; Voriconazole [USAN:INN:BAN]; Voriconazole (JAN/USAN/INN); (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol; (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol; (R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; (alphaR,betaS)-alpha-(2,4-Difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; (alphaR,betaS)-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; VRC

Indication

Disease Entry	ICD 11	Status	REF
Aspergillosis	1F20	Approved	[1]
Candidiasis	1F23	Approved	[1]
Fusariosis	N.A.	Approved	[1]
Invasive aspergillosis	1F20.0	Approved	[2]
Invasive candidiasis	1F23	Approved	[1]
Neuroaspergillosis	N.A.	Approved	[1]
Candidemia	1F23.3Y	Investigative	[1]
Esophageal candidiasis	N.A.	Investigative	[1]

• Therapeutic Class: Antifungal Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 349.31
  Logarithm of the Partition Coefficient (xlogp); 1.5
  Rotatable Bond Count (rotbonds); 5
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 8
• ADMET Property:
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1-2 h [3]
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
  Bioavailability: The bioavailability of drug is 96% [3]
  Clearance: The clearance of drug is 5.25-7 L/h in healthy adults [5]
  Elimination: Voriconazole is eliminated via hepatic metabolism with less than 2% of the dose excreted unchanged in the urine [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 5.6 hours [6]
  Metabolism: The drug is metabolized via the hepatic [7]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 34.35442 micromolar/kg/day [8]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.42% [6]
  Vd: The volume of distribution (Vd) of drug is 4.6 L/kg [3]
  Water Solubility: The ability of drug to dissolve in water is measured as 0.39 mg/mL [4]
• Chemical Identifiers:
  Formula: C16H14F3N5O
  IUPAC Name: (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol
  Canonical SMILES: C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O
  InChI: InChI=1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1
  InChIKey: BCEHBSKCWLPMDN-MGPLVRAMSA-N
• Cross-matching ID:
  PubChem CID: 71616
  ChEBI ID: CHEBI:10023
  CAS Number: 188416-29-7
  DrugBank ID: DB00582
  TTD ID: D0N3VR
  VARIDT ID: DR00445
  INTEDE ID: DR1709
  ACDINA ID: D00733
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Candida Cytochrome P450 51 (Candi ERG11)	TTTSOUD	CP51_CANAL	Modulator	[9]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[10]
Cytochrome P450 2C9 (CYP2C9) Main DME	DE5IED8	CP2C9_HUMAN	Substrate	[11]
Mephenytoin 4-hydroxylase (CYP2C19) Main DME	DEGTFWK	CP2CJ_HUMAN	Substrate	[11]
Prostaglandin G/H synthase 1 (COX-1)	DE073H6	PGH1_HUMAN	Substrate	[12]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Carbonic anhydrase 1 (CA1)	OTNFBVVQ	CAH1_HUMAN	Gene/Protein Processing	[13]
Carbonic anhydrase 2 (CA2)	OTJRMUAG	CAH2_HUMAN	Gene/Protein Processing	[13]
Cytochrome P450 1B1 (CYP1B1)	OTYXFLSD	CP1B1_HUMAN	Gene/Protein Processing	[14]
Cytochrome P450 2C19 (CYP2C19)	OTFMJYYE	CP2CJ_HUMAN	Gene/Protein Processing	[15]
Cytochrome P450 2C9 (CYP2C9)	OTGLBN29	CP2C9_HUMAN	Gene/Protein Processing	[15]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Gene/Protein Processing	[15]
Lanosterol 14-alpha demethylase (CYP51A1)	OTAYHG9C	CP51A_HUMAN	Drug Response	[16]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Voriconazole

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Posaconazole	DMUL5EW	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Posaconazole.	Aspergillosis [1F20]	[17]

Coadministration of a Drug Treating the Disease Different from Voriconazole (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Voriconazole and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[18]
Clindamycin	DM15HL8	Moderate	Decreased metabolism of Voriconazole caused by Clindamycin mediated inhibition of CYP450 enzyme.	Acne vulgaris [ED80]	[19]
Tretinoin	DM49DUI	Major	Decreased metabolism of Voriconazole caused by Tretinoin mediated inhibition of CYP450 enzyme.	Acne vulgaris [ED80]	[20]
Repaglinide	DM5SXUV	Moderate	Decreased metabolism of Voriconazole caused by Repaglinide mediated inhibition of CYP450 enzyme.	Acute diabete complication [5A2Y]	[21]
Glibenclamide	DM8JXPZ	Major	Decreased metabolism of Voriconazole caused by Glibenclamide mediated inhibition of CYP450 enzyme.	Acute diabete complication [5A2Y]	[22]
Tolazamide	DMIHRNA	Major	Decreased metabolism of Voriconazole caused by Tolazamide mediated inhibition of CYP450 enzyme.	Acute diabete complication [5A2Y]	[22]
Pioglitazone	DMKJ485	Moderate	Decreased metabolism of Voriconazole caused by Pioglitazone mediated inhibition of CYP450 enzyme.	Acute diabete complication [5A2Y]	[18]
Nateglinide	DMLK2QH	Moderate	Decreased metabolism of Voriconazole caused by Nateglinide mediated inhibition of CYP450 enzyme.	Acute diabete complication [5A2Y]	[23]
Glipizide	DMZA5PQ	Major	Decreased metabolism of Voriconazole caused by Glipizide mediated inhibition of CYP450 enzyme.	Acute diabete complication [5A2Y]	[22]
Ivosidenib	DM8S6T7	Major	Decreased metabolism of Voriconazole caused by Ivosidenib mediated inhibition of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[24]
Midostaurin	DMI6E0R	Major	Decreased metabolism of Voriconazole caused by Midostaurin mediated inhibition of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[25]
Idarubicin	DMM0XGL	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Idarubicin.	Acute myeloid leukaemia [2A60]	[17]
Daunorubicin	DMQUSBT	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Daunorubicin.	Acute myeloid leukaemia [2A60]	[26]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Voriconazole caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[27]
Oliceridine	DM6MDCF	Major	Decreased metabolism of Voriconazole caused by Oliceridine mediated inhibition of CYP450 enzyme.	Acute pain [MG31]	[28]
Mitotane	DMU1GX0	Moderate	Increased metabolism of Voriconazole caused by Mitotane mediated induction of CYP450 enzyme.	Adrenal cancer [2D11]	[27]
Galantamine	DMEO794	Moderate	Decreased metabolism of Voriconazole caused by Galantamine mediated inhibition of CYP450 enzyme.	Alzheimer disease [8A20]	[29]
Rivastigmine	DMG629M	Moderate	Increased risk of ventricular arrhythmias by the combination of Voriconazole and Rivastigmine.	Alzheimer disease [8A20]	[17]
Donepezil	DMIYG7Z	Minor	Decreased metabolism of Voriconazole caused by Donepezil mediated inhibition of CYP450 enzyme.	Alzheimer disease [8A20]	[30]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Voriconazole and Metronidazole.	Amoebiasis [1A36]	[18]
Ivabradine	DM0L594	Major	Decreased metabolism of Voriconazole caused by Ivabradine mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[18]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Voriconazole and Bepridil.	Angina pectoris [BA40]	[17]
Dronedarone	DMA8FS5	Major	Decreased metabolism of Voriconazole caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[18]
Nifedipine	DMSVOZT	Moderate	Decreased metabolism of Voriconazole caused by Nifedipine mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[31]
Bedaquiline	DM3906J	Major	Decreased metabolism of Voriconazole caused by Bedaquiline mediated inhibition of CYP450 enzyme.	Antimicrobial drug resistance [MG50-MG52]	[32]
Clorazepate	DMC3JST	Moderate	Decreased metabolism of Voriconazole caused by Clorazepate mediated inhibition of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[18]
Methylphenobarbital	DMDSWAG	Major	Increased metabolism of Voriconazole caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[17]
Cilostazol	DMZMSCT	Major	Decreased metabolism of Voriconazole caused by Cilostazol mediated inhibition of CYP450 enzyme.	Arterial occlusive disease [BD40]	[23]
Levalbuterol	DM5YBO1	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Levalbuterol.	Asthma [CA23]	[33]
Terbutaline	DMD4381	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Terbutaline.	Asthma [CA23]	[34]
Pirbuterol	DMI5678	Moderate	Increased risk of ventricular arrhythmias by the combination of Voriconazole and Pirbuterol.	Asthma [CA23]	[34]
Budesonide	DMJIBAW	Major	Decreased metabolism of Voriconazole caused by Budesonide mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[35]
Salbutamol	DMN9CWF	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Salbutamol.	Asthma [CA23]	[33]
Formoterol	DMSOURV	Moderate	Increased risk of ventricular arrhythmias by the combination of Voriconazole and Formoterol.	Asthma [CA23]	[34]
Zileuton	DMVRIC2	Moderate	Decreased metabolism of Voriconazole caused by Zileuton mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[18]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[23]
Desipramine	DMT2FDC	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[17]
Ofloxacin	DM0VQN3	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[36]
Clarithromycin	DM4M1SG	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[17]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Voriconazole and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[17]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Voriconazole and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[36]
Gemifloxacin	DMHT34O	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[36]
Norfloxacin	DMIZ6W2	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[36]
Rabeprazole	DMMZXIW	Moderate	Decreased metabolism of Voriconazole caused by Rabeprazole mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[37]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Voriconazole caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[18]
Lomefloxacin	DMVRH9C	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[17]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Retigabine.	Behcet disease [4A62]	[17]
Cariprazine	DMJYDVK	Major	Decreased metabolism of Voriconazole caused by Cariprazine mediated inhibition of CYP450 enzyme.	Bipolar disorder [6A60]	[38]
Erdafitinib	DMI782S	Major	Decreased metabolism of Voriconazole caused by Erdafitinib mediated inhibition of CYP450 enzyme.	Bladder cancer [2C94]	[39]
Pexidartinib	DMS2J0Z	Major	Decreased metabolism of Voriconazole caused by Pexidartinib mediated inhibition of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[40]
Loperamide	DMOJZQ9	Major	Decreased metabolism of Voriconazole caused by Loperamide mediated inhibition of CYP450 enzyme.	Bowel habit change [ME05]	[41]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Eribulin.	Breast cancer [2C60-2C6Y]	[17]
Ixabepilone	DM2OZ3G	Moderate	Decreased metabolism of Voriconazole caused by Ixabepilone mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[42]
Lapatinib	DM3BH1Y	Major	Decreased metabolism of Voriconazole caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[18]
HKI-272	DM6QOVN	Major	Decreased metabolism of Voriconazole caused by HKI-272 mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[43]
LY2835219	DM93VBZ	Major	Decreased metabolism of Voriconazole caused by LY2835219 mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[44]
Esterified estrogens	DM9KZDO	Moderate	Decreased metabolism of Voriconazole caused by Esterified estrogens mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[45]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Voriconazole caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[46]
Palbociclib	DMD7L94	Major	Decreased metabolism of Voriconazole caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[47]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Voriconazole caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[48]
Quinestrol	DMJ6H1Z	Moderate	Decreased metabolism of Voriconazole caused by Quinestrol mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[45]
Tamoxifen	DMLB0EZ	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Tamoxifen.	Breast cancer [2C60-2C6Y]	[17]
Cabazitaxel	DMPAZHC	Moderate	Decreased metabolism of Voriconazole caused by Cabazitaxel mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[18]
Bosutinib	DMTI8YE	Major	Decreased metabolism of Voriconazole caused by Bosutinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[18]
Trastuzumab Emtansine	DMU1LXS	Moderate	Decreased metabolism of Voriconazole caused by Trastuzumab Emtansine mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[18]
Estradiol	DMUNTE3	Moderate	Decreased metabolism of Voriconazole caused by Estradiol mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[45]
Atorvastatin	DMF28YC	Major	Decreased metabolism of Voriconazole caused by Atorvastatin mediated inhibition of CYP450 enzyme.	Cardiovascular disease [BA00-BE2Z]	[49]
Macitentan	DMP79A1	Major	Decreased metabolism of Voriconazole caused by Macitentan mediated inhibition of CYP450 enzyme.	Cardiovascular disease [BA00-BE2Z]	[50]
PF-04449913	DMSB068	Major	Decreased metabolism of Voriconazole caused by PF-04449913 mediated inhibition of CYP450 enzyme.	Chronic myelomonocytic leukaemia [2A40]	[51]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Voriconazole and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[34]
Salmeterol	DMIEU69	Major	Decreased metabolism of Voriconazole caused by Salmeterol mediated inhibition of CYP450 enzyme.	Chronic obstructive pulmonary disease [CA22]	[18]
Indacaterol	DMQJHR7	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[34]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Voriconazole and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[34]
Levomilnacipran	DMV26S8	Major	Decreased metabolism of Voriconazole caused by Levomilnacipran mediated inhibition of CYP450 enzyme.	Chronic pain [MG30]	[52]
Anisindione	DM2C48U	Major	Decreased metabolism of Voriconazole caused by Anisindione mediated inhibition of CYP450 enzyme.	Coagulation defect [3B10]	[27]
Regorafenib	DMHSY1I	Moderate	Decreased metabolism of Voriconazole caused by Regorafenib mediated inhibition of CYP450 enzyme.	Colorectal cancer [2B91]	[18]
Irinotecan	DMP6SC2	Major	Decreased metabolism of Voriconazole caused by Irinotecan mediated inhibition of CYP450 enzyme.	Colorectal cancer [2B91]	[17]
Isoproterenol	DMK7MEY	Moderate	Increased risk of ventricular arrhythmias by the combination of Voriconazole and Isoproterenol.	Conduction disorder [BC63]	[33]
Drospirenone	DM1A9W3	Major	Decreased metabolism of Voriconazole caused by Drospirenone mediated inhibition of CYP450 enzyme.	Contraceptive management [QA21]	[18]
Levonorgestrel	DM1DP7T	Moderate	Decreased metabolism of Voriconazole caused by Levonorgestrel mediated inhibition of CYP450 enzyme.	Contraceptive management [QA21]	[45]
Ulipristal	DMBNI20	Minor	Decreased metabolism of Voriconazole caused by Ulipristal mediated inhibition of CYP450 enzyme.	Contraceptive management [QA21]	[23]
Levobupivacaine	DM783CH	Moderate	Decreased metabolism of Voriconazole caused by Levobupivacaine mediated inhibition of CYP450 enzyme.	Corneal disease [9A76-9A78]	[23]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Halothane.	Corneal disease [9A76-9A78]	[17]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Sevoflurane.	Corneal disease [9A76-9A78]	[17]
Cocaine	DMSOX7I	Moderate	Decreased metabolism of Voriconazole caused by Cocaine mediated inhibition of CYP450 enzyme.	Corneal disease [9A76-9A78]	[18]
Alfentanil	DMVO0UB	Major	Decreased metabolism of Voriconazole caused by Alfentanil mediated inhibition of CYP450 enzyme.	Corneal disease [9A76-9A78]	[53]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Probucol.	Coronary atherosclerosis [BA80]	[17]
Clofazimine	DMEBOFW	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Clofazimine.	Crohn disease [DD70]	[54]
Mifepristone	DMGZQEF	Major	Decreased metabolism of Voriconazole caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[55]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Voriconazole and Pasireotide.	Cushing syndrome [5A70]	[17]
Osilodrostat	DMIJC9X	Major	Decreased metabolism of Voriconazole caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[23]
Ivacaftor	DMZC1HS	Major	Decreased metabolism of Voriconazole caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[18]
MK-8228	DMOB58Q	Moderate	Increased metabolism of Voriconazole caused by MK-8228 mediated induction of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[56]
Rivaroxaban	DMQMBZ1	Major	Decreased clearance of Voriconazole due to the transporter inhibition by Rivaroxaban.	Deep vein thrombosis [BD71]	[18]
Aprepitant	DM053KT	Moderate	Decreased metabolism of Voriconazole caused by Aprepitant mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[57]
Trimipramine	DM1SC8M	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Trimipramine.	Depression [6A70-6A7Z]	[17]
Cyclobenzaprine	DM1YBRM	Moderate	Decreased metabolism of Voriconazole caused by Cyclobenzaprine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[18]
Vilazodone	DM4LECQ	Major	Decreased metabolism of Voriconazole caused by Vilazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[58]
Nefazodone	DM4ZS8M	Moderate	Decreased metabolism of Voriconazole caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[18]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Voriconazole and Escitalopram.	Depression [6A70-6A7Z]	[17]
OPC-34712	DMHG57U	Major	Decreased metabolism of Voriconazole caused by OPC-34712 mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[59]
Clomipramine	DMINRKW	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Clomipramine.	Depression [6A70-6A7Z]	[17]
Trazodone	DMK1GBJ	Moderate	Decreased metabolism of Voriconazole caused by Trazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[60]
Doxepin	DMPI98T	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Doxepin.	Depression [6A70-6A7Z]	[17]
Maprotiline	DMPWB7T	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Maprotiline.	Depression [6A70-6A7Z]	[17]
Polatuzumab vedotin	DMF6Y0L	Major	Decreased metabolism of Voriconazole caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme.	Diffuse large B-cell lymphoma [2A81]	[61]
[3H]estrone-3-sulphate	DMGPF0N	Moderate	Decreased metabolism of Voriconazole caused by [3H]estrone-3-sulphate mediated inhibition of CYP450 enzyme.	Discovery agent [N.A.]	[62]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[17]
Ospemifene	DMC4GEI	Moderate	Decreased metabolism of Voriconazole caused by Ospemifene mediated inhibition of CYP450 enzyme.	Dyspareunia [GA12]	[63]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Deutetrabenazine.	Dystonic disorder [8A02]	[64]
Ingrezza	DMVPLNC	Major	Additive CNS depression effects by the combination of Voriconazole and Ingrezza.	Dystonic disorder [8A02]	[65]
Diazepam	DM08E9O	Moderate	Decreased metabolism of Voriconazole caused by Diazepam mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[66]
Zonisamide	DM0DTF7	Moderate	Decreased metabolism of Voriconazole caused by Zonisamide mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[18]
Primidone	DM0WX6I	Major	Increased metabolism of Voriconazole caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[17]
Felbamate	DM1V5ZS	Moderate	Increased metabolism of Voriconazole caused by Felbamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[27]
Oxcarbazepine	DM5PU6O	Moderate	Increased metabolism of Voriconazole caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[27]
Ethosuximide	DMDZ9LT	Moderate	Decreased metabolism of Voriconazole caused by Ethosuximide mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[18]
Cenobamate	DM8KLU9	Moderate	Decreased metabolism of Voriconazole caused by Cenobamate mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[67]
Tiagabine	DMKSQG0	Moderate	Decreased metabolism of Voriconazole caused by Tiagabine mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[18]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Voriconazole caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[23]
Fosphenytoin	DMOX3LB	Major	Increased metabolism of Voriconazole caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[68]
Brivaracetam	DMSEPK8	Minor	Decreased metabolism of Voriconazole caused by Brivaracetam mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[23]
Clonazepam	DMTO13J	Moderate	Decreased metabolism of Voriconazole caused by Clonazepam mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[18]
Lacosamide	DMVM6QR	Moderate	Decreased metabolism of Voriconazole caused by Lacosamide mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[18]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Voriconazole caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[23]
Phenobarbital	DMXZOCG	Major	Increased metabolism of Voriconazole caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[17]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Voriconazole caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[27]
Cannabidiol	DM0659E	Minor	Decreased metabolism of Voriconazole caused by Cannabidiol mediated inhibition of CYP450 enzyme.	Epileptic encephalopathy [8A62]	[23]
Nicardipine	DMCDYW7	Moderate	Decreased metabolism of Voriconazole caused by Nicardipine mediated inhibition of CYP450 enzyme.	Essential hypertension [BA00]	[31]
Mefenamic acid	DMK7HFI	Moderate	Decreased metabolism of Voriconazole caused by Mefenamic acid mediated inhibition of CYP450 enzyme.	Female pelvic pain [GA34]	[18]
Bay 80-6946	DMLOS5R	Major	Decreased metabolism of Voriconazole caused by Bay 80-6946 mediated inhibition of CYP450 enzyme.	Follicular lymphoma [2A80]	[69]
Tazemetostat	DMWP1BH	Major	Decreased metabolism of Voriconazole caused by Tazemetostat mediated inhibition of CYP450 enzyme.	Follicular lymphoma [2A80]	[70]
Solifenacin	DMG592Q	Major	Decreased metabolism of Voriconazole caused by Solifenacin mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[18]
Mirabegron	DMS1GYT	Minor	Decreased metabolism of Voriconazole caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[71]
Tolterodine	DMSHPW8	Moderate	Decreased metabolism of Voriconazole caused by Tolterodine mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[72]
Itraconazole	DMCR1MV	Moderate	Decreased metabolism of Voriconazole caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[18]
Pentamidine	DMHZJCG	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Pentamidine.	Fungal infection [1F29-1F2F]	[17]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Voriconazole caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[18]
Ketoconazole	DMPZI3Q	Moderate	Decreased metabolism of Voriconazole caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[18]
Cisapride	DMY7PED	Major	Decreased metabolism of Voriconazole caused by Cisapride mediated inhibition of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[73]
Ripretinib	DM958QB	Major	Decreased metabolism of Voriconazole caused by Ripretinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[18]
Avapritinib	DMK2GZX	Major	Decreased metabolism of Voriconazole caused by Avapritinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[23]
Colchicine	DM2POTE	Major	Decreased metabolism of Voriconazole caused by Colchicine mediated inhibition of CYP450 enzyme.	Gout [FA25]	[74]
Sulfinpyrazone	DMEV954	Moderate	Increased metabolism of Voriconazole caused by Sulfinpyrazone mediated induction of CYP450 enzyme.	Gout [FA25]	[27]
Ergotamine	DMKR3C5	Major	Decreased metabolism of Voriconazole caused by Ergotamine mediated inhibition of CYP450 enzyme.	Headache [8A80-8A84]	[75]
Eplerenone	DMF0NQR	Major	Decreased metabolism of Voriconazole caused by Eplerenone mediated inhibition of CYP450 enzyme.	Heart failure [BD10-BD1Z]	[18]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Voriconazole caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[76]
Simeprevir	DMLUA9D	Major	Decreased metabolism of Voriconazole caused by Simeprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[18]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Voriconazole caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[76]
Daclatasvir	DMSFK9V	Major	Decreased metabolism of Voriconazole caused by Daclatasvir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[23]
Rifampin	DMA8J1G	Major	Increased metabolism of Voriconazole caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[17]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Voriconazole caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[77]
Brentuximab vedotin	DMWLC57	Moderate	Decreased clearance of Voriconazole due to the transporter inhibition by Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[27]
MK-1439	DM215WE	Minor	Decreased metabolism of Voriconazole caused by MK-1439 mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[78]
Delavirdine	DM3NF5G	Moderate	Decreased metabolism of Voriconazole caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[27]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Voriconazole caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[79]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Voriconazole caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[80]
Tipranavir	DM8HJX6	Moderate	Decreased metabolism of Voriconazole caused by Tipranavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[81]
Efavirenz	DMC0GSJ	Major	Increased metabolism of Voriconazole caused by Efavirenz mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[82]
Dolutegravir	DMCZGRE	Minor	Decreased metabolism of Voriconazole caused by Dolutegravir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[83]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Voriconazole and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[84]
Etravirine	DMGV8QU	Moderate	Decreased metabolism of Voriconazole caused by Etravirine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[85]
Rilpivirine	DMJ0QOW	Moderate	Decreased metabolism of Voriconazole caused by Rilpivirine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[86]
Amprenavir	DMLMXE0	Moderate	Decreased metabolism of Voriconazole caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Atazanavir	DMSYRBX	Moderate	Decreased metabolism of Voriconazole caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Maraviroc	DMTL94F	Major	Decreased metabolism of Voriconazole caused by Maraviroc mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[87]
Simvastatin	DM30SGU	Major	Decreased metabolism of Voriconazole caused by Simvastatin mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[88]
Fluvastatin	DM4MDJY	Moderate	Decreased metabolism of Voriconazole caused by Fluvastatin mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[18]
Fenofibrate	DMFKXDY	Moderate	Decreased metabolism of Voriconazole caused by Fenofibrate mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[18]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Voriconazole and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[89]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Voriconazole and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[17]
BMS-201038	DMQTAGO	Major	Decreased metabolism of Voriconazole caused by BMS-201038 mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[18]
Cinacalcet	DMCX0K3	Moderate	Decreased metabolism of Voriconazole caused by Cinacalcet mediated inhibition of CYP450 enzyme.	Hyper-parathyroidism [5A51]	[90]
Paricalcitol	DMYBV3G	Moderate	Decreased metabolism of Voriconazole caused by Paricalcitol mediated inhibition of CYP450 enzyme.	Hyper-parathyroidism [5A51]	[23]
Aliskiren	DM1BV7W	Moderate	Decreased clearance of Voriconazole due to the transporter inhibition by Aliskiren.	Hypertension [BA00-BA04]	[17]
Losartan	DM72JXH	Moderate	Decreased metabolism of Voriconazole caused by Losartan mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[18]
Levamlodipine	DM92S6N	Moderate	Decreased metabolism of Voriconazole caused by Levamlodipine mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[31]
Doxazosin	DM9PLRH	Moderate	Decreased metabolism of Voriconazole caused by Doxazosin mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[17]
Verapamil	DMA7PEW	Moderate	Decreased metabolism of Voriconazole caused by Verapamil mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[31]
Felodipine	DMOSW35	Moderate	Decreased metabolism of Voriconazole caused by Felodipine mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[31]
Irbesartan	DMTP1DC	Moderate	Decreased metabolism of Voriconazole caused by Irbesartan mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[18]
Tolvaptan	DMIWFRL	Major	Decreased metabolism of Voriconazole caused by Tolvaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[18]
Fludrocortisone	DMUDIR8	Moderate	Decreased metabolism of Voriconazole caused by Fludrocortisone mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[91]
Pirfenidone	DM6VZFQ	Moderate	Decreased metabolism of Voriconazole caused by Pirfenidone mediated inhibition of CYP450 enzyme.	Idiopathic interstitial pneumonitis [CB03]	[23]
Retapamulin	DM9JXB7	Minor	Decreased metabolism of Voriconazole caused by Retapamulin mediated inhibition of CYP450 enzyme.	Impetigo [1B72]	[92]
Lesinurad	DMUR64T	Moderate	Decreased metabolism of Voriconazole caused by Lesinurad mediated inhibition of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[93]
TP-434	DM5A31S	Minor	Decreased metabolism of Voriconazole caused by TP-434 mediated inhibition of CYP450 enzyme.	Infectious gastroenteritis/colitis [1A40]	[94]
Suvorexant	DM0E6S3	Major	Decreased metabolism of Voriconazole caused by Suvorexant mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[18]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Voriconazole caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[27]
Ramelteon	DM7IW9J	Moderate	Decreased metabolism of Voriconazole caused by Ramelteon mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[95]
Flurazepam	DMAL4G0	Moderate	Decreased metabolism of Voriconazole caused by Flurazepam mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[18]
Triazolam	DMETYK5	Major	Decreased metabolism of Voriconazole caused by Triazolam mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[96]
Zaleplon	DMGFWSM	Moderate	Decreased metabolism of Voriconazole caused by Zaleplon mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[18]
Tasimelteon	DMLOQ1V	Moderate	Decreased metabolism of Voriconazole caused by Tasimelteon mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[97]
ITI-007	DMUQ1DO	Major	Decreased metabolism of Voriconazole caused by ITI-007 mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[98]
Quazepam	DMY4D87	Moderate	Decreased metabolism of Voriconazole caused by Quazepam mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[18]
Estazolam	DMZGXUM	Moderate	Decreased metabolism of Voriconazole caused by Estazolam mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[18]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Voriconazole and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[23]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Voriconazole and Phenolphthalein.	Irritable bowel syndrome [DD91]	[17]
Alosetron	DML2A03	Moderate	Decreased metabolism of Voriconazole caused by Alosetron mediated inhibition of CYP450 enzyme.	Irritable bowel syndrome [DD91]	[99]
Eluxadoline	DMYZ0P1	Moderate	Decreased metabolism of Voriconazole caused by Eluxadoline mediated inhibition of CYP450 enzyme.	Irritable bowel syndrome [DD91]	[100]
Naloxegol	DML0B41	Major	Decreased metabolism of Voriconazole caused by Naloxegol mediated inhibition of CYP450 enzyme.	Large intestine motility disorder [DB32]	[18]
Testosterone	DM7HUNW	Moderate	Decreased metabolism of Voriconazole caused by Testosterone mediated inhibition of CYP450 enzyme.	Low bone mass disorder [FB83]	[18]
Crizotinib	DM4F29C	Major	Decreased metabolism of Voriconazole caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[18]
Brigatinib	DM7W94S	Major	Decreased metabolism of Voriconazole caused by Brigatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[101]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Voriconazole and Porfimer Sodium.	Lung cancer [2C25]	[102]
Ceritinib	DMB920Z	Major	Decreased metabolism of Voriconazole caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[18]
Lurbinectedin	DMEFRTZ	Major	Decreased metabolism of Voriconazole caused by Lurbinectedin mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[103]
PF-06463922	DMKM7EW	Major	Decreased metabolism of Voriconazole caused by PF-06463922 mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[104]
Osimertinib	DMRJLAT	Major	Decreased metabolism of Voriconazole caused by Osimertinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[105]
Pralsetinib	DMWU0I2	Major	Decreased metabolism of Voriconazole caused by Pralsetinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[106]
Capmatinib	DMYCXKL	Major	Decreased metabolism of Voriconazole caused by Capmatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[107]
Selpercatinib	DMZR15V	Major	Decreased metabolism of Voriconazole caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[23]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Voriconazole and Lumefantrine.	Malaria [1F40-1F45]	[18]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Voriconazole and Halofantrine.	Malaria [1F40-1F45]	[108]
Chloroquine	DMSI5CB	Major	Increased risk of prolong QT interval by the combination of Voriconazole and Chloroquine.	Malaria [1F40-1F45]	[109]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Voriconazole and Hydroxychloroquine.	Malaria [1F40-1F45]	[109]
Primaquine	DMWQ16I	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Primaquine.	Malaria [1F40-1F45]	[17]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[23]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Voriconazole and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[110]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Voriconazole and Idelalisib.	Mature B-cell leukaemia [2A82]	[111]
IPI-145	DMWA24P	Major	Decreased metabolism of Voriconazole caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[112]
Arsenic trioxide	DM61TA4	Major	Increased risk of prolong QT interval by the combination of Voriconazole and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[113]
Acalabrutinib	DM7GCVW	Major	Decreased metabolism of Voriconazole caused by Acalabrutinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[114]
Ibrutinib	DMHZCPO	Major	Decreased metabolism of Voriconazole caused by Ibrutinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[18]
Ponatinib	DMYGJQO	Major	Decreased metabolism of Voriconazole caused by Ponatinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[18]
Selumetinib	DMC7W6R	Major	Decreased metabolism of Voriconazole caused by Selumetinib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[115]
LGX818	DMNQXV8	Major	Decreased metabolism of Voriconazole caused by LGX818 mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[116]
Dabrafenib	DMX6OE3	Moderate	Decreased metabolism of Voriconazole caused by Dabrafenib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[18]
Estrone	DM5T6US	Moderate	Decreased metabolism of Voriconazole caused by Estrone mediated inhibition of CYP450 enzyme.	Menopausal disorder [GA30]	[45]
Dienestrol	DMBSXI0	Moderate	Decreased metabolism of Voriconazole caused by Dienestrol mediated inhibition of CYP450 enzyme.	Menopausal disorder [GA30]	[62]
Ethinyl estradiol	DMODJ40	Moderate	Decreased metabolism of Voriconazole caused by Ethinyl estradiol mediated inhibition of CYP450 enzyme.	Menopausal disorder [GA30]	[62]
Ubrogepant	DM749I3	Major	Decreased metabolism of Voriconazole caused by Ubrogepant mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[117]
Almogran	DM7I64Z	Moderate	Decreased metabolism of Voriconazole caused by Almogran mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[118]
Rimegepant	DMHOAUG	Moderate	Decreased metabolism of Voriconazole caused by Rimegepant mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[119]
Exjade	DMHPRWG	Moderate	Increased metabolism of Voriconazole caused by Exjade mediated induction of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[27]
Flibanserin	DM70DTN	Major	Decreased metabolism of Voriconazole caused by Flibanserin mediated inhibition of CYP450 enzyme.	Mood disorder [6A60-6E23]	[120]
Midazolam	DMXOELT	Major	Decreased metabolism of Voriconazole caused by Midazolam mediated inhibition of CYP450 enzyme.	Mood/affect symptom [MB24]	[96]
Panobinostat	DM58WKG	Major	Decreased metabolism of Voriconazole caused by Panobinostat mediated inhibition of CYP450 enzyme.	Multiple myeloma [2A83]	[121]
Thalidomide	DM70BU5	Moderate	Increased risk of ventricular arrhythmias by the combination of Voriconazole and Thalidomide.	Multiple myeloma [2A83]	[18]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Voriconazole and Siponimod.	Multiple sclerosis [8A40]	[18]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Voriconazole and Fingolimod.	Multiple sclerosis [8A40]	[17]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Voriconazole and Ozanimod.	Multiple sclerosis [8A40]	[122]
Deflazacort	DMV0RNS	Major	Decreased metabolism of Voriconazole caused by Deflazacort mediated inhibition of CYP450 enzyme.	Muscular dystrophy [8C70]	[23]
Rifabutin	DM1YBHK	Major	Increased metabolism of Voriconazole caused by Rifabutin mediated induction of CYP450 enzyme.	Mycobacterium infection [1B10-1B21]	[27]
Romidepsin	DMT5GNL	Moderate	Decreased metabolism of Voriconazole caused by Romidepsin mediated inhibition of CYP450 enzyme.	Mycosis fungoides [2B01]	[123]
Fedratinib	DM4ZBK6	Major	Decreased metabolism of Voriconazole caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[23]
Nilotinib	DM7HXWT	Major	Decreased metabolism of Voriconazole caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[18]
Dasatinib	DMJV2EK	Major	Decreased metabolism of Voriconazole caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[18]
Vorapaxar	DMA16BR	Major	Decreased metabolism of Voriconazole caused by Vorapaxar mediated inhibition of CYP450 enzyme.	Myocardial infarction [BA41-BA43]	[18]
Modafinil	DMYILBE	Moderate	Increased metabolism of Voriconazole caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[27]
Promethazine	DM6I5GR	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Promethazine.	Nausea/vomiting [MD90]	[17]
Granisetron	DMIUW25	Moderate	Decreased metabolism of Voriconazole caused by Granisetron mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[18]
Dolasetron	DMMG26Z	Major	Increased risk of prolong QT interval by the combination of Voriconazole and Dolasetron.	Nausea/vomiting [MD90]	[17]
Ondansetron	DMOTQ1I	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Ondansetron.	Nausea/vomiting [MD90]	[17]
E-2007	DMJDYNQ	Minor	Decreased metabolism of Voriconazole caused by E-2007 mediated inhibition of CYP450 enzyme.	Neuropathy [8C0Z]	[23]
Entrectinib	DMMPTLH	Major	Decreased metabolism of Voriconazole caused by Entrectinib mediated inhibition of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[18]
Levomethadyl Acetate	DM06HG5	Major	Decreased metabolism of Voriconazole caused by Levomethadyl Acetate mediated inhibition of CYP450 enzyme.	Opioid use disorder [6C43]	[124]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Lofexidine.	Opioid use disorder [6C43]	[17]
S-297995	DM26IH8	Moderate	Decreased metabolism of Voriconazole caused by S-297995 mediated inhibition of CYP450 enzyme.	Opioid use disorder [6C43]	[23]
Diclofenac	DMPIHLS	Moderate	Decreased metabolism of Voriconazole caused by Diclofenac mediated inhibition of CYP450 enzyme.	Osteoarthritis [FA00-FA05]	[18]
Olaparib	DM8QB1D	Major	Decreased metabolism of Voriconazole caused by Olaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[18]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Rucaparib.	Ovarian cancer [2C73]	[17]
Dextropropoxyphene	DM23HCX	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Dextropropoxyphene.	Pain [MG30-MG3Z]	[26]
Butorphanol	DM5KYPJ	Major	Decreased metabolism of Voriconazole caused by Butorphanol mediated inhibition of CYP450 enzyme.	Pain [MG30-MG3Z]	[125]
Ibuprofen	DM8VCBE	Moderate	Decreased metabolism of Voriconazole caused by Ibuprofen mediated inhibition of CYP450 enzyme.	Pain [MG30-MG3Z]	[18]
Buprenorphine	DMPRI8G	Moderate	Decreased metabolism of Voriconazole caused by Buprenorphine mediated inhibition of CYP450 enzyme.	Pain [MG30-MG3Z]	[126]
Hydrocodone	DMQ2JO5	Major	Decreased metabolism of Voriconazole caused by Hydrocodone mediated inhibition of CYP450 enzyme.	Pain [MG30-MG3Z]	[127]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Triclabendazole.	Parasitic worm infestation [1F90]	[17]
Istradefylline	DM20VSK	Major	Decreased metabolism of Voriconazole caused by Istradefylline mediated inhibition of CYP450 enzyme.	Parkinsonism [8A00]	[128]
Pimavanserin	DMR7IVC	Major	Decreased metabolism of Voriconazole caused by Pimavanserin mediated inhibition of CYP450 enzyme.	Parkinsonism [8A00]	[129]
Bromocriptine	DMVE3TK	Moderate	Decreased metabolism of Voriconazole caused by Bromocriptine mediated inhibition of CYP450 enzyme.	Parkinsonism [8A00]	[18]
Apomorphine	DMX38HQ	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Apomorphine.	Parkinsonism [8A00]	[17]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Voriconazole caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[130]
Esomeprazole	DM7BN0X	Moderate	Decreased metabolism of Voriconazole caused by Esomeprazole mediated inhibition of CYP450 enzyme.	Peptic ulcer [DA61]	[37]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Voriconazole and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[131]
Lefamulin	DME6G97	Major	Decreased metabolism of Voriconazole caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[132]
Prednisone	DM2HG4X	Moderate	Decreased metabolism of Voriconazole caused by Prednisone mediated inhibition of CYP450 enzyme.	Postoperative inflammation [1A00-CA43]	[91]
Hydrocortisone	DMGEMB7	Moderate	Decreased metabolism of Voriconazole caused by Hydrocortisone mediated inhibition of CYP450 enzyme.	Postoperative inflammation [1A00-CA43]	[91]
Ergonovine	DM0VEC1	Major	Decreased metabolism of Voriconazole caused by Ergonovine mediated inhibition of CYP450 enzyme.	Postpartum haemorrhage [JA43]	[133]
Ritodrine	DM4V6RL	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Ritodrine.	Preterm labour/delivery [JB00]	[34]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Degarelix.	Prostate cancer [2C82]	[23]
ABIRATERONE	DM8V75C	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and ABIRATERONE.	Prostate cancer [2C82]	[23]
Nilutamide	DMFN07X	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Nilutamide.	Prostate cancer [2C82]	[23]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Voriconazole caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[27]
Darolutamide	DMV7YFT	Minor	Decreased metabolism of Voriconazole caused by Darolutamide mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[134]
Bicalutamide	DMZMSPF	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Bicalutamide.	Prostate cancer [2C82]	[23]
Tamsulosin	DM5QF9V	Major	Decreased metabolism of Voriconazole caused by Tamsulosin mediated inhibition of CYP450 enzyme.	Prostate hyperplasia [GA90]	[18]
Silodosin	DMJSBT6	Major	Decreased metabolism of Voriconazole caused by Silodosin mediated inhibition of CYP450 enzyme.	Prostate hyperplasia [GA90]	[18]
Dutasteride	DMQ4TJK	Moderate	Decreased metabolism of Voriconazole caused by Dutasteride mediated inhibition of CYP450 enzyme.	Prostate hyperplasia [GA90]	[135]
Finasteride	DMWV3TZ	Moderate	Decreased metabolism of Voriconazole caused by Finasteride mediated inhibition of CYP450 enzyme.	Prostate hyperplasia [GA90]	[18]
Levomepromazine	DMIKFEL	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Levomepromazine.	Psychotic disorder [6A20-6A25]	[17]
Fluphenazine	DMIT8LX	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Fluphenazine.	Psychotic disorder [6A20-6A25]	[17]
Ambrisentan	DMD1QXW	Minor	Decreased metabolism of Voriconazole caused by Ambrisentan mediated inhibition of CYP450 enzyme.	Pulmonary hypertension [BB01]	[136]
Riociguat	DMXBLMP	Moderate	Decreased clearance of Voriconazole due to the transporter inhibition by Riociguat.	Pulmonary hypertension [BB01]	[18]
Everolimus	DM8X2EH	Major	Decreased metabolism of Voriconazole caused by Everolimus mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[18]
Axitinib	DMGVH6N	Major	Decreased metabolism of Voriconazole caused by Axitinib mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[18]
Temsirolimus	DMS104F	Major	Increased metabolism of Voriconazole caused by Temsirolimus mediated induction of CYP450 enzyme.	Renal cell carcinoma [2C90]	[18]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Voriconazole and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[137]
Ciclesonide	DM2NA4K	Moderate	Decreased metabolism of Voriconazole caused by Ciclesonide mediated inhibition of CYP450 enzyme.	Respiratory system disease [CB40-CB7Z]	[91]
Meloxicam	DM2AR7L	Moderate	Decreased metabolism of Voriconazole caused by Meloxicam mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[18]
Upadacitinib	DM32B5U	Major	Decreased metabolism of Voriconazole caused by Upadacitinib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[138]
Tofacitinib	DMBS370	Major	Decreased metabolism of Voriconazole caused by Tofacitinib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[18]
Flurbiprofen	DMGN4BY	Moderate	Decreased metabolism of Voriconazole caused by Flurbiprofen mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[18]
Dexamethasone	DMMWZET	Moderate	Decreased metabolism of Voriconazole caused by Dexamethasone mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[139]
Nafcillin	DMN9RPO	Moderate	Increased metabolism of Voriconazole caused by Nafcillin mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[27]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Voriconazole and Leflunomide.	Rheumatoid arthritis [FA20]	[17]
Quetiapine	DM1N62C	Major	Decreased metabolism of Voriconazole caused by Quetiapine mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[140]
Mesoridazine	DM2ZGAN	Major	Increased risk of prolong QT interval by the combination of Voriconazole and Mesoridazine.	Schizophrenia [6A20]	[17]
Thioridazine	DM35M8J	Major	Increased risk of prolong QT interval by the combination of Voriconazole and Thioridazine.	Schizophrenia [6A20]	[17]
Aripiprazole	DM3NUMH	Moderate	Decreased metabolism of Voriconazole caused by Aripiprazole mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[141]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Voriconazole and Iloperidone.	Schizophrenia [6A20]	[17]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Paliperidone.	Schizophrenia [6A20]	[17]
Trifluoperazine	DMKBYWI	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Trifluoperazine.	Schizophrenia [6A20]	[17]
Risperidone	DMN6DXL	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Risperidone.	Schizophrenia [6A20]	[17]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Voriconazole and Amisulpride.	Schizophrenia [6A20]	[18]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Asenapine.	Schizophrenia [6A20]	[17]
Pimozide	DMW83TP	Major	Decreased metabolism of Voriconazole caused by Pimozide mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[18]
Fentanyl	DM8WAHT	Major	Decreased metabolism of Voriconazole caused by Fentanyl mediated inhibition of CYP450 enzyme.	Sensation disturbance [MB40]	[18]
Sufentanil	DMU7YEL	Moderate	Decreased metabolism of Voriconazole caused by Sufentanil mediated inhibition of CYP450 enzyme.	Sensation disturbance [MB40]	[142]
Avanafil	DM75CXN	Major	Decreased metabolism of Voriconazole caused by Avanafil mediated inhibition of CYP450 enzyme.	Sexual dysfunction [HA00-HA01]	[18]
Tadalafil	DMJZHT1	Moderate	Decreased metabolism of Voriconazole caused by Tadalafil mediated inhibition of CYP450 enzyme.	Sexual dysfunction [HA00-HA01]	[18]
Vardenafil	DMTBGW8	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Vardenafil.	Sexual dysfunction [HA00-HA01]	[17]
Voxelotor	DMCS6M5	Major	Decreased metabolism of Voriconazole caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[143]
LDE225	DMM9F25	Major	Decreased metabolism of Voriconazole caused by LDE225 mediated inhibition of CYP450 enzyme.	Skin cancer [2C30-2C37]	[144]
Larotrectinib	DM26CQR	Major	Decreased metabolism of Voriconazole caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[18]
Docetaxel	DMDI269	Major	Decreased clearance of Voriconazole due to the transporter inhibition by Docetaxel.	Solid tumour/cancer [2A00-2F9Z]	[145]
Trabectedin	DMG3Y89	Major	Decreased metabolism of Voriconazole caused by Trabectedin mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[18]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Voriconazole and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[146]
Etoposide	DMNH3PG	Moderate	Decreased metabolism of Voriconazole caused by Etoposide mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[18]
Prednisolone	DMQ8FR2	Moderate	Decreased metabolism of Voriconazole caused by Prednisolone mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[91]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Voriconazole and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[17]
Norethindrone	DMTY169	Moderate	Decreased metabolism of Voriconazole caused by Norethindrone mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[62]
Taxol	DMUOT9V	Moderate	Decreased metabolism of Voriconazole caused by Taxol mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[147]
Doxorubicin	DMVP5YE	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[26]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Pitolisant.	Somnolence [MG42]	[17]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[17]
Ivermectin	DMDBX5F	Moderate	Decreased metabolism of Voriconazole caused by Ivermectin mediated inhibition of CYP450 enzyme.	Strongyloidiasis [1F6B]	[23]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Voriconazole and Naltrexone.	Substance abuse [6C40]	[148]
Warfarin	DMJYCVW	Major	Decreased metabolism of Voriconazole caused by Warfarin mediated inhibition of CYP450 enzyme.	Supraventricular tachyarrhythmia [BC81]	[27]
Adenosine	DMM2NSK	Moderate	Increased risk of ventricular arrhythmias by the combination of Voriconazole and Adenosine.	Supraventricular tachyarrhythmia [BC81]	[17]
Pomalidomide	DMTGBAX	Moderate	Decreased metabolism of Voriconazole caused by Pomalidomide mediated inhibition of CYP450 enzyme.	Systemic sclerosis [4A42]	[18]
Fostamatinib	DM6AUHV	Major	Decreased metabolism of Voriconazole caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[149]
As-1670542	DMV05SW	Moderate	Decreased metabolism of Voriconazole caused by As-1670542 mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[23]
Apixaban	DM89JLN	Major	Decreased clearance of Voriconazole due to the transporter inhibition by Apixaban.	Thrombosis [DB61-GB90]	[18]
Brilinta	DMBR01X	Major	Decreased metabolism of Voriconazole caused by Brilinta mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[18]
Clopidogrel	DMOL54H	Moderate	Decreased metabolism of Voriconazole caused by Clopidogrel mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[150]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Lenvatinib.	Thyroid cancer [2D10]	[17]
Cabozantinib	DMIYDT4	Major	Decreased metabolism of Voriconazole caused by Cabozantinib mediated inhibition of CYP450 enzyme.	Thyroid cancer [2D10]	[18]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Voriconazole and Papaverine.	Tonus and reflex abnormality [MB47]	[151]
Tizanidine	DMR2IQ4	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Tizanidine.	Tonus and reflex abnormality [MB47]	[17]
Sirolimus	DMGW1ID	Major	Decreased metabolism of Voriconazole caused by Sirolimus mediated inhibition of CYP450 enzyme.	Transplant rejection [NE84]	[17]
Tacrolimus	DMZ7XNQ	Major	Decreased metabolism of Voriconazole caused by Tacrolimus mediated inhibition of CYP450 enzyme.	Transplant rejection [NE84]	[152]
Tolbutamide	DM02AWV	Major	Decreased metabolism of Voriconazole caused by Tolbutamide mediated inhibition of CYP450 enzyme.	Type 2 diabetes mellitus [5A11]	[22]
Saxagliptin	DMGXENV	Moderate	Decreased metabolism of Voriconazole caused by Saxagliptin mediated inhibition of CYP450 enzyme.	Type 2 diabetes mellitus [5A11]	[23]
Chlorpropamide	DMPHZQE	Major	Decreased metabolism of Voriconazole caused by Chlorpropamide mediated inhibition of CYP450 enzyme.	Type 2 diabetes mellitus [5A11]	[22]
Elagolix	DMB2C0E	Major	Decreased metabolism of Voriconazole caused by Elagolix mediated inhibition of CYP450 enzyme.	Uterine fibroid [2E86]	[153]
Fexofenadine	DM17ONX	Minor	Decreased clearance of Voriconazole due to the transporter inhibition by Fexofenadine.	Vasomotor/allergic rhinitis [CA08]	[154]
Astemizole	DM2HN6Q	Major	Decreased metabolism of Voriconazole caused by Astemizole mediated inhibition of CYP450 enzyme.	Vasomotor/allergic rhinitis [CA08]	[155]
Triamcinolone	DM98IXF	Major	Decreased metabolism of Voriconazole caused by Triamcinolone mediated inhibition of CYP450 enzyme.	Vasomotor/allergic rhinitis [CA08]	[91]
Trimeprazine	DMEMV9D	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[26]
Fluticasone	DMGCSVF	Major	Decreased metabolism of Voriconazole caused by Fluticasone mediated inhibition of CYP450 enzyme.	Vasomotor/allergic rhinitis [CA08]	[156]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Voriconazole and Procainamide.	Ventricular tachyarrhythmia [BC71]	[17]
Propafenone	DMPIBJK	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Propafenone.	Ventricular tachyarrhythmia [BC71]	[17]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Voriconazole and Flecainide.	Ventricular tachyarrhythmia [BC71]	[17]
Amiodarone	DMUTEX3	Major	Decreased metabolism of Voriconazole caused by Amiodarone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[157]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Carmellose sodium	E00625	Not Available	Disintegrant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 3350	E00652	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000	E00655	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Voriconazole 200 mg tablet	200 mg	Oral Tablet	Oral
Voriconazole 50 mg tablet	50 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Voriconazole FDA Label
• [2] Disk diffusion test and E-test with enriched Mueller-Hinton agar for determining susceptibility of Candida species to voriconazole and fluconazole. J Microbiol Immunol Infect. 2009 Apr;42(2):148-53.
• [3] VFEND? FDA Label
• [4] BDDCS applied to over 900 drugs
• [5] Shi C, Xiao Y, Mao Y, Wu J, Lin N: Voriconazole: A Review of Population Pharmacokinetic Analyses. Clin Pharmacokinet. 2019 Jun;58(6):687-703. doi: 10.1007/s40262-019-00735-7.
• [6] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [7] Deen M, Correnti E, Kamm K, Kelderman T, Papetti L, Rubio-Beltran E, Vigneri S, Edvinsson L, Maassen Van Den Brink A: Blocking CGRP in migraine patients - a review of pros and cons. J Headache Pain. 2017 Sep 25;18(1):96. doi: 10.1186/s10194-017-0807-1.
• [8] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [9] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [10] Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. Biochem Pharmacol. 2007 Jun 15;73(12):2020-6.
• [11] Effect of voriconazole on the pharmacokinetics of diclofenac. Fundam Clin Pharmacol. 2007 Dec;21(6):651-6.
• [12] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [13] Inhibition profiles of Voriconazole against acetylcholinesterase, -glycosidase, and human carbonic anhydrase I and II isoenzymes. J Biochem Mol Toxicol. 2019 Oct;33(10):e22385. doi: 10.1002/jbt.22385. Epub 2019 Sep 3.
• [14] Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
• [15] The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
• [16] Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homolo... Antimicrob Agents Chemother. 2008 Oct;52(10):3597-603.
• [17] Canadian Pharmacists Association.
• [18] Cerner Multum, Inc. "Australian Product Information.".
• [19] Product Information. Cleocin (clindamycin). Pharmacia and Upjohn, Kalamazoo, MI.
• [20] Adamson PC "Pharmacokinetics of all-trans-retinoic acid: clinical implications in acute promyelocytic leukemia." Semin Hematol 31 (1994): 14-7. [PMID: 7831580]
• [21] Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14. [PMID: 12919179]
• [22] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
• [23] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [24] Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
• [25] Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
• [26] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
• [27] Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
• [28] Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
• [29] Product Information. Reminyl (galantamine) Janssen Pharmaceuticals, Titusville, NJ.
• [30] Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
• [31] Heinig R, Adelmann HG, Ahr G "The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine." Eur J Clin Pharmacol 55 (1999): 57-60. [PMID: 10206086]
• [32] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [33] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [34] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [35] Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
• [36] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
• [37] Eiden C, Peyriere H, Tichit R, et al. "Inherited long QT syndrome revealed by antifungals drug-drug interaction." J Clin Pharm Ther 32 (2007): 321-4. [PMID: 17489884]
• [38] Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
• [39] Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
• [40] Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
• [41] Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
• [42] Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
• [43] Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
• [44] Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
• [45] Devenport MH, Crook D, Wynn V, Lees LJ "Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives." Br J Clin Pharmacol 27 (1989): 851-9. [PMID: 2547410]
• [46] Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
• [47] Product Information. Ibrance (palbociclib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [48] Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
• [49] Akram K, Rao S, Parker M "A lesson for everyone in drug-drug interactions." Int J Cardiol 118 (2007): e19-20. [PMID: 17368833]
• [50] Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
• [51] Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [52] Product Information. Fetzima (levomilnacipran). Forest Pharmaceuticals, St. Louis, MO.
• [53] Bartkowski RR, Goldberg ME, Larijani GE, Boerner T "Inhibition of alfentanil metabolism by erythromycin." Clin Pharmacol Ther 46 (1989): 99-102. [PMID: 2501060]
• [54] Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
• [55] Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
• [56] Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
• [57] Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
• [58] Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
• [59] Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
• [60] Dattilo PB, Nordin C "Prolonged QT associated with an overdose of trazodone." J Clin Psychiatry 68 (2007): 1309-10. [PMID: 17854263]
• [61] Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
• [62] Lazar JD, Wilner KD "Drug interactions with fluconazole." Rev Infect Dis 12 Suppl 3 (1990): s327-33. [PMID: 2330488]
• [63] Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
• [64] Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
• [65] Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
• [66] Ahonen J, Olkkola KT, Neuvonen PJ "The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam." Fundam Clin Pharmacol 10 (1996): 314-8. [PMID: 8836707]
• [67] Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
• [68] Alffenaar JW, van der Elst KC, Uges DR, Kosterink JG, Daenen SM "Phenytoin-induced reduction of voriconazole serum concentration is not compensated by doubling the dosage." Br J Clin Pharmacol 68 (2009): 462-3. [PMID: 19740405]
• [69] Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
• [70] Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
• [71] Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
• [72] Brynne N, Forslund C, Hallen B, Gustafsson LL, Bertilsson L "Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity." Br J Clin Pharmacol 48 (1999): 564-72. [PMID: 10583027]
• [73] Bedford TA, Rowbotham DJ "Cisapride: drug interactions of clinical significance." Drug Saf 15 (1996): 167-75. [PMID: 8879971]
• [74] Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K "Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure." J Nephrol 19 (2006): 515-7. [PMID: 17048210]
• [75] Ausband SC, Goodman PE "An unusual case of clarithromycin associated ergotism." J Emerg Med 4 (2001): 411-3. [PMID: 11728770]
• [76] Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
• [77] Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
• [78] Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
• [79] Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
• [80] Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
• [81] Product Information. Aptivus (tipranavir). Boehringer-Ingelheim, Ridgefield, CT.
• [82] Carbonara S, Regazzi M, Ciraci E, et al. "Long-term Efficacy and safety of TDM-assisted combination of voriconazole plus efavirenz in an AIDS patient with cryptococcosis and liver cirrhosis." Ann Pharmacother 43 (2009): 978-84. [PMID: 19383934]
• [83] Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
• [84] Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
• [85] Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
• [86] Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
• [87] Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [88] Ayanian JZ, Fuchs CS, Stone RM "Lovastatin and rhabdomyolysis." Ann Intern Med 109 (1988): 682-3. [PMID: 3421582]
• [89] Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
• [90] Product Information. Sensipar (cinacalcet). Amgen USA, Thousand Oaks, CA.
• [91] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
• [92] Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
• [93] Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [94] Product Information. Xerava (eravacycline). Tetraphase Pharmaceuticals, Inc, Watertown, MA.
• [95] Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
• [96] Ahonen J, Olkkola KT, Neuvonen PJ "Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers." Br J Clin Pharmacol 40 (1995): 270-2. [PMID: 8527290]
• [97] Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
• [98] Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
• [99] Product Information. Lotronex (alosetron). Glaxo Wellcome, Research Triangle Park, NC.
• [100] Product Information. Viberzi (eluxadoline). Actavis Pharma, Inc., Parsippany, NJ.
• [101] Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
• [102] Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
• [103] Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
• [104] Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [105] Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [106] Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
• [107] Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [108] Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
• [109] Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
• [110] Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
• [111] Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
• [112] Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
• [113] Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
• [114] Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [115] Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [116] Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
• [117] Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
• [118] Product Information. Axert (almotriptan) Pharmacia and Upjohn, Kalamazoo, MI.
• [119] Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
• [120] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [121] Hamberg P, Woo MM, Chen LC, et al. "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor." Cancer Chemother Pharmacol 68 (2011): 805-13. [PMID: 21706316]
• [122] Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
• [123] Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
• [124] Product Information. Orlaam (levomethadyl acetate) Roxanne Laboratories Inc, Columbus, OH.
• [125] Product Information. Butorphanol Tartrate (butorphanol). Apotex Corporation, Weston, FL.
• [126] Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
• [127] Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA "CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes." Br J Clin Pharmacol 57 (2004): 287-97. [PMID: 14998425]
• [128] Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
• [129] Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
• [130] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [131] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [132] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [133] Blanche P, Rigolet A, Gombert B, Ginsburg C, Salmon D, Sicard D "Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir." Postgrad Med J 75 (1999): 546-7. [PMID: 10616689]
• [134] Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
• [135] Product Information. Duagen (dutasteride). GlaxoSmithKline Healthcare, Pittsburgh, PA.
• [136] Product Information. Letairis (ambrisentan). Gilead Sciences, Foster City, CA.
• [137] Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
• [138] Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
• [139] Edsbacker S, Andersson T "Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease." Clin Pharmacokinet 43 (2004): 803-21. [PMID: 15355126]
• [140] DeVane CL, Nemeroff CB "Clinical pharmacokinetics of quetiapine - An atypical antipsychotic." Clin Pharmacokinet 40 (2001): 509-22. [PMID: 11510628]
• [141] Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
• [142] Bartkowski RR, Goldberg ME, Huffnagle S, Epstein RH "Sufentanil disposition. Is it affected by erythromycin administration?" Anesthesiology 78 (1993): 260-5. [PMID: 8439020]
• [143] Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
• [144] Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
• [145] Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
• [146] Product Information. Kisqali (ribociclib). Novartis Pharmaceuticals, East Hanover, NJ.
• [147] Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):. [PMID: 26446447]
• [148] Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
• [149] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
• [150] Collet JP, Hulot JS, Pena A, et al. "Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study." Lancet 373 (2009): 309-17. [PMID: 19108880]
• [151] Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
• [152] Albengres E, Le Louet H, Tillement JP "Systemic antifungal agents. Drug interactions of clinical significance." Drug Saf 18 (1998): 83-97. [PMID: 9512916]
• [153] Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
• [154] Product Information. Allegra (fexofenadine). Hoechst Marion-Roussel Inc, Kansas City, MO.
• [155] Ament PW, Paterson A "Drug interactions with the nonsedating antihistamines." Am Fam Physician 56 (1997): 223. [PMID: 9225677]
• [156] Arrington-Sanders R, Hutton N, Siberry GK "Ritonavir-fluticasone interaction causing Cushing syndrome in HIV-infected children and adolescents." Pediatr Infect Dis J 25 (2006): 1044-1048. [PMID: 17072128]
• [157] Fabre G, Julian B, Saint-Aubert B, Joyeux H, Berger Y "Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions." Drug Metab Dispos 21 (1993): 978-85. [PMID: 7905403]